Qing Li

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 8

Top Topics

Epithelial Mesenchymal Transition

Skeletal Muscle

Top Venues

Human psychopharmacology

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Rong Liu, You Zou, Wei-Quan Wang, Jun-Hong Chen, Lei Zhang, Jia Feng, Ji-Ye Yin, Xiao-Yuan Mao, Qing Li, Zhi-Ying Luo, Wei Zhang, Dao-Ming Wang
Gut microbial structural variation associates with immune checkpoint inhibitor response. Nature communications 14 (1) (2023)
Shiwei Zhou, Obinna N Obianom, Jiangsheng Huang, Dong Guo, Hong Yang, Qing Li, Yan Shu
RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. Pharmaceutics 2021, 13 , 330. Pharmaceutics 15 (6) (2023)
Rong Zhou, Haijun Yang, Peng Zhu, Yujie Liu, Yanjuan Zhang, Wei Zhang, Honghao Zhou, Xiong Li, Qing Li
Effect of Gut Microbiota on the Pharmacokinetics of Nifedipine in Spontaneously Hypertensive Rats. Pharmaceutics 15 (8) (2023)
Shiwei Zhou, Obinna N Obianom, Jiangsheng Huang, Dong Guo, Hong Yang, Qing Li, Yan Shu
RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. Pharmaceutics 2021, 13 , 330. Pharmaceutics 15 (6) (2023)
Jingyi Chen, Nian Yang, Yilei Peng, Honghao Zhou, Qing Li
Association between Nonfood Pre- or Probiotic Use and Cognitive Function: Results from NHANES 2011-2014. Nutrients 15 (15) (2023)
Shiwei Zhou, Obinna N Obianom, Jiangsheng Huang, Dong Guo, Hong Yang, Qing Li, Yan Shu
Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. Pharmaceutics 13 (3) (2021)
Hong Yang, Shiwei Zhou, Dong Guo, Obinna N Obianom, Qing Li, Yan Shu
Divergent Regulation of OCT and MATE Drug Transporters by Cadmium Exposure. Pharmaceutics 13 (4) (2021)
Zongping Xiong, Ming Cheng, Peng Zhu, Shiqiong Huang, Jun Guo, Wei Zhang, Honghao Zhou, Yan Shu, Qing Li
Association of blood cell counts with the risk of olanzapine- or clozapine-induced dyslipidemia in Chinese schizophrenia patients. Human psychopharmacology 34 (4) (2019)